Women's Bodies, Women's Wisdom (198 page)

62
. C. E. Cann, M. C. Martin, and R. B. Jaffe, “Decreased Spinal Mineral Content in Amenorrheic Women,”
Journal of the American Medical Association,
vol. 25, no.

5 (1984), pp. 626–29; J. S. Lindberg, M. R. Powell, et al., “Increased Vertebral Bone Mineral in Response to Reduced Exercise in Amenorrheic Runners,”
Western
Journal of Medicine,
vol. 146 (1987), pp. 39–42; R. Marcus et al., “Menstrual Function and Bone Mass in Elite Women Distance Runners,”
Annals of Internal
Medicine,
vol. 102 (1985), pp. 158–63; J. C. Prior, “Spinal Bone Loss and Ovula-tory Disturbances,”
New England Journal of Medicine,
vol. 323, no. 18 (November 1, 1990), pp. 1221–27.

63
. W. S. Browner et al., “Mortality Following Fractures in Older Women: The Study of Osteoporotic Fracture,”
Archives of Internal Medicine,
vol. 156 (1996), pp. 1521–25; P. Dargen-Molina et al., “Fall-Related Factors and Risk of Hip Fracture: The EPI-DOX Prospective Study,”
The Lancet,
vol. 348 (1996), pp. 148–49.

64
. L. Avioli, “Osteoporosis: A Growing National Health Problem,”
Female Patient,
vol. 17 (1992), pp. 25–28; W. A. Wallace, “The Increasing Incidence of Fractures of the Proximal Femur: An Orthopaedic Epidemic,”
The Lancet,
vol. 1, no. 833 (June 25, 1993), p. 1413.

65
. H. Bischoff-Ferrari, “Effect of Extended Physiotherapy and High-Dose Vitamin D on Rate of Falls and Hospital Re-admission After Acute Hip Fracture: A Randomized Controlled Trial,” presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), September 2009, Denver, CO.

66
. L. S. Harkness et al., “Decreased Bone Resorption with Soy Isoflavone Supplementation in Postmenopausal Women,”
Journal of Women’s Health (Larchmont),
vol. 13, no. 9 (Nov. 2004), pp. 1000–7; M. Mori et al., “Soy Isoflavone Tablets Reduce Osteoporosis Risk Factors and Obesity in Middle-Aged Japanese Women,”
Clinical and Experimental Pharmacology and Physiology,
vol. 31, suppl. 2 (Dec. 2004), pp. S39–41; M. Mori et al., “Soy Isoflavones Improve Bone Metabolism in Postmenopausal Japanese Women,”
Clinical and Experimental
Pharmacology and Physiology,
vol. 31, suppl. 2 (Dec. 2004), pp. S44–46; E. Nikander et al., “Effects of Phytoestrogens on Bone Turnover in Postmenopausal Women with a History of Breast Cancer,”
Journal of Clinical Endocrinology and
Metabolism,
vol. 89, no. 3 (March 2004), pp. 1207–12.

67
. Urasopon et al., “
Pueraria mirifica,
a Phytoestrogen-Rich Herb, Prevents Bone Loss in Orchidectomized Rats.”

68
. D. Feskanich, W. C. Willett, and G. A. Colditz, “Calcium, Vitamin D, Milk Consumption, and Hip Fractures: A Prospective Study Among Postmenopausal Women,”
American Journal of Clinical Nutrition,
vol. 77, no. 2 (Feb. 2003), pp. 504–11.

69
. H. A. Bischoff-Ferrari et al., “Calcium Intake and Hip Fracture Risk in Men and Women: A Meta-Analysis of Prospective Cohort Studies and Randomized Controlled Trials,”
American Journal of Clinical Nutrition,
vol. 86, no. 6 (December 2007), pp. 1780–90.

70
. M. Castleman, “The Calcium Myth,”
Natural Solutions
(July/August 2009), pp. 57–62, available online at
www.naturalsolutionsmag.com
www.naturalsolutionsmag.com/articles-display/15403/The-Calcium-Myth
.

71
. M. Hernandez-Avila et al., “Caffeine, Moderate Alcohol Intake, and Risk of Fracture of the Hip and Forearm in Middle-Aged Women,”
American Journal of Clinical
Nutrition,
vol. 54 (1991), pp. 157–63; D. E. Nelson, R. W. Suttin, J. A. Langois, et al., “Alcohol as a Risk Factor for Fall Injury Events Among Elderly Persons Living in the Community,”
Journal of the Geriatric Society,
vol. 40 (1992), pp. 658–61; H. D. Nelson et al., “Smoking, Alcohol, and Neuromuscular and Physical Function of Older Women,”
Journal of the American Medical Association,
vol. 272, no. 24 (1994), pp. 1909–13.

72
. D. C. Bauer et al., “Factors Associated with Appendicular Bone Mass in Older Women,”
Archives of Internal Medicine,
vol. 118, no. 9 (1993), pp. 657–65; D. P. Kiel et al., “Caffeine and the Risk of Hip Fracture: The Framingham Study,”
Biological
Psychiatry,
vol. 23 (1988), pp. 335–49.

73
. M. F. Holick, “Optimal Vitamin D Status for the Prevention and Treatment of Osteoporosis,”
Drugs and Aging,
vol. 24, no. 12 (2007), pp. 1017–29.

74
. R. Vieth, “The Role of Vitamin D in the Prevention of Osteoporosis,”
Annals of
Medicine,
vol. 37, no. 4 (2005), pp. 276–77.

75
. Feskanich, Willett, and Colditz, “Calcium, Vitamin D, Milk Consumption, and Hip Fractures: A Prospective Study Among Postmenopausal Women.”

76
. B. Dawson-Hughes et al., “Effect of Vitamin D Supplementation on Wintertime and Overall Bone Loss in Healthy Postmenopausal Women,”
Annals of Internal
Medicine,
vol. 115, no. 17 (1991), pp. 505–12.

77
. H. I. Abdalla, D. M. Hart, et al., “Prevention of Bone Mineral Loss in Postmenopausal Women by Norethisterone,”
Obstetrics and Gynecology,
vol. 66 (1985), pp. 789–92; J. Dequeker and E. De Muylder, “Long-Term Progestogen Treatment and Bone Remodeling in Premenopausal Women; A Longitudinal Study,”
Maturitas,
vol. 4 (1982), pp. 309–13; R. Lindsay, D. M. Hart, D. Purdee, et al., “Comparative Effectiveness of Estrogen and a Progestogen on Bone Loss in Postmenopausal Women,”
Clinical Science and Molecular Medicine,
vol. 54 (1978), pp. 93–95; J. McCann and N. Horwitz, “Provera Alone Builds Bone,”
Medical Tribune,
July 1987, pp. 4–5; J. C. Prior et al., “Progesterone as a Bone-Tropic Hormone,”
Endocrine Reviews,
vol. 11 (1990), pp. 386–98; B. L. Riggs, J. Jowsery, P. J. Kelly, et al., “Effect of Sex Hormones in Bone in Primary Osteoporosis,”
Journal of Clinical Investigations,
vol. 48 (1969), pp. 1065–72; F. G. R. Snow and C. Anderson, “The Effect of 17-Beta Estradiol and Progestogen on Tra-becular Bone Remodeling in Oophorectomized Dogs,”
Calcification Tissue,
vol. 39 (1986), pp. 198–205.

78
. A. K. Banerjee, P. J. Lane, and F. W. Meichen, “Vitamin C and Osteoporosis in Old Age,”
Age and Aging,
vol. 7, no. 1 (1978), pp. 16–18.

79
. F. H. Nielsen, “Studies on the Relationship Between Boron and Magnesium Which Possibly Affects the Formation and Maintenance of Bones,”
Magnesium
Trace Elements,
vol. 9, no. 2 (1990), pp. 61–91; J. U. Reginster et al., “Preliminary Report of Decreased Serum Magnesium in Post-Menopausal Osteoporosis,”
Magnesium,
vol. 8, no. 2 (1989), pp. 106–9.

80
. T. L. Holbrook et al., “Dietary Calcium and Risk of Hip Fracture: A 14-Year Prospective Population Study,”
The Lancet,
vol. 2 (1988), pp. 1046–9; H. Spencer et al., “Absorption of Calcium in Osteoporosis,”
American Journal of Medicine,
vol. 37 (1964), pp. 223–24.

81
. F. H. Nielsen et al., “Effects of Dietary Boron on Mineral, Estrogen, and Testosterone Metabolism in Post-Menopausal Women,”
Federation of American Societies
for Experimental Biology Journal,
vol. 1 (1987), pp. 394–97.

82
. C. V. Odvina et al., “Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy,”
Journal of Clinical Endocrinology and Metabolism,
vol. 90, no. 3 (March 2005), pp. 1294–301.

83
. D. C. Bauer et al., “Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial,”
Journal
of Bone and Mineral Research,
vol. 19, no. 8 (Aug. 2004), pp. 1250–8; E. B. Kwek et al., “An Emerging Pattern of Subtrochanteric Stress Fractures: A Long-Term Complication of Alendronate Therapy?”
Injury,
vol. 39, no. 2, (Feb. 2008), pp. 224–31; A. S. Neviaser et al., “Low-Energy Femoral Shaft Fractures Associated with Alendronate Use,”
Journal of Orthopaedic Trauma,
vol. 22, no. 5 (May–June 2008), pp. 346–50; T. Parker–Pope, “Drugs to Build Bones May Weaken Them,”
New York Times
(July 15, 2008), available online at
www.nytimes.com/2008/07/15/health/15well.html?partner=rssnyt&emc=rss
; R. K. Cheung et al., “Sequential Non-Traumatic Femoral Shaft Fractures in a Patient on Long-Term Alendronate,”
Hong Kong Medical Journal,
vol. 13, no. 6 (Dec. 2007), pp. 485–89.

84
. P. Alonso-Coello et al., “Drugs for Pre-Osteoporosis: Prevention or Disease Mongering?”
British Medical Journal,
vol. 336, no. 7636 (January 19, 2008), pp. 126–29.

85
. 32nd Annual San Antonio Breast Cancer Symposium (SABCS): Abstracts 21 and 27. Presented December 10, 2009.

86
. S. L. Ruggiero et al., “Osteonecrosis of the Jaws Associated with the Use of Bis-phosphonates: A Review of 63 Cases,”
Journal of Oral and Maxillofacial Surgery,
vol. 62, no. 5 (May 2004), pp. 527–34.

87
. Leon Speroff, “Is Long-Term Alendronate Treatment a Problem?”
Ob/Gyn Clinical
Alert,
vol. 22, no. 2 (June 1, 2005), pp. 9–10.

88
. U. Hartmann et al., “Low Sexual Desire in Midlife and Older Women: Personality Factors, Psychosocial Development, Present Sexuality,”
Menopause,
vol. 11, no. 6, pt. 2 (Nov./Dec. 2004), pp. 726–40; R. Basson, “Recent Advances in Women’s Sexual Function and Dysfunction,”
Menopause,
vol. 11, no. 6, pt. 2 (Nov./Dec. 2004), pp. 714–25;
NAMS Supplement—Update on Sexuality at
Menopause and Beyond: Normative, Adaptive, Problematic, Dysfunctional,
North American Menopause Society, vol. 11, no. 6 (Nov. 2004), pp. 708–86; P. Sarrel and M. I. Whitehead, “Sex and Menopause: Defining the Issues,”
Matu-ritas,
vol. 7 (1985) pp. 217–24; R. H. van Lunsen and E. Laan, “Genital Vascular Responsiveness and Sexual Feelings in Midlife Women: Psychophysiologic, Brain, and Genital Imaging Studies,”
Menopause,
vol. 11, no. 6, pt. 2 (Nov./Dec. 2004), pp. 741–48.

89
. Gina Ogden,
The Return of Desire
(Boston: Trumpeter, 2008).

90
. Lisa M. Diamond,
Sexual Fluidity: Understanding Women’s Love and Desire
(Cambridge, MA: Harvard University Press, 2008).

91
. B. Zumoff, B. W. Strain, L. K. Miller, and W. Roser, “24-Hour Mean Plasma Testosterone Concentration Declines with Age in Normal Premenopausal Women,”
Journal of Clinical Endocrinology and Metabolism,
vol. 80, no. 4 (1995), pp. 1429–30.

92
. G. A. Bachmann, “Correlates of Sexual Desire in Postmenopausal Women,”
Ma-turitas,
vol. 7, no. 3 (1985), p. 211, cited in David Youngs, “Common Misconceptions About Sex and Depression During Menopause: A Historical Perspective,”
Female Patient,
vol. 17 (1992), pp. 25–28; Pfenninger, “Sex and the Maturing Female”; J. R. Wilson, “Sexuality in Aging,” in J. J. Sciarra, ed.,
Gynecology and
Obstetrics
(Philadelphia: Lippincott, 1987), pp. 1–12.

93
. Bachmann, “Correlates of Sexual Desire.”

94
. Harry Fisch with Stephen Braun,
The Male Biological Clock: The Startling News
About Aging, Sexuality, and Fertility in Men
(New York: Free Press, 2005).

95
. Personal communication with Dr. Alan Gaby (a specialist in nutritional medicine); personal communication with David Zava, Ph.D., Aeron Lifecycles Lab.

96
. Mantak Chia and Maneewan Chia,
Cultivating Female Sexual Energy: Healing
Love Through the Tao
(Huntington, NY: Healing Tao Books, 1986); available from Healing Tao Books, 2 Creskill Place, Huntington, NY 11743.

97
. J. K. Meyers, M. M. Weissman, and G. L. Tischler, “Six-Month Prevalence of Psychiatric Disorder in Three Communities,”
Archives of General Psychiatry,
vol. 41 (1984), p. 959.

98
. S. M. McKinlay, J. B. McKinlay, and D. J. Bramblilla, “Health Status and Utilization Behavior Associated with Menopause,”
American Journal of Epidemiology,
vol. 125 (1987), p. 110.

99
. M. Murray, “HRT vs. Remifemin in Menopause,”
American Journal of Natural
Medicine,
vol. 3, no. 4 (1996), pp. 7–10; Warnecke, “Beeinflussing.”

100
. S. Hozl, L. Demisch, and B. Gollnik, “Investigations About Antidepressive and Mood Change Effects of
Hypericum Perforatum,
”
Planta Medica,
vol. 55 (1989), p. 643.

101
. Marian Van Eck McCain,
Transformation Through Menopause
(Amherst, MA: Bergin and Garvey, 1991).

102
. Marguerite Holloway, “The Estrogen Factor,”
Scientific American
(June 1992).